Gong K, Wen D Y, Ouyang T, Rao A T, Herzberg M C
Department of Preventive Sciences, School of Dentistry, University of Minnesota, Minneapolis 55455, USA.
Infect Immun. 1995 Sep;63(9):3628-33. doi: 10.1128/iai.63.9.3628-3633.1995.
Platelets aggregate in response to an adhesin and the platelet aggregation-associated protein (PAAP) expressed on the cell surfaces of certain strains of Streptococcus sanguis. We sought to identify the corresponding PAAP receptor and accessory adhesin binding sites on platelets. Since the adhesion(s) of S. sanguis for platelets has not been characterized, an anti-idiotype (anti-id) murine monoclonal antibody (MAb2) strategy was developed. First, MAb1s that distinguished the adhesin and PAAP antigens on the surface of S. sanguis I 133-79 were selected. Fab fragments of MAb1.2 (immunoglobulin G2b [IgG2b]; 70 pmol) reacted with 5 x 10(7) cells of S. sanguis to completely inhibit the aggregation of human platelets in plasma. Under similar conditions, MAb1.1 (IgG1) inhibited the adhesion of S. sanguis cells to platelets by a maximum of 34%, with a comparatively small effect on platelet aggregation. Together, these two MAb1s inhibited S. sanguis-platelet adhesion by 63%. In Western immunoblots, both MAb1s reacted with S. sanguis 133-79 87- and 150-kDa surface proteins and MAb1.2 also reacted with purified type I collagen. The hybridomas producing MAb1.1 and MAb1.2 were then injected into BALB/c mice. Enlarged spleens were harvested, and a panel of MAb2 hybridomas was prepared. To identify anti-ids against the specific MAb1s, the MAb2 panel was screened by enzyme-linked immunosorbent assay for reaction with rabbit polyclonal IgG antibodies against the 87- and 150-kDa antigens. The reactions between the specific rabbit antibodies and anti-ids were inhibited by the 87- and 150-kDa antigens. When preincubated with platelets, MAb2.1 (counterpart of MAb1.1) inhibited adhesion to platelets maximally by 46% and MAb2.2 (anti-MAb1.2) inhibited adhesion to platelets maximally by 35%. Together, both MAb2s inhibited the adhesion of S. sanguis to platelets by 81%. MAb2.2 also inhibited induction of platelet aggregation. MAb2.2 immunoprecipitated a biotinylated platelet membrane antigen of 170 kDa (unreduced); MAb2.1 precipitated membrane antigens of 175- and 230-kDa (unreduced). Therefore, platelet binding sites and the receptor for the S. sanguis adhesin and PAAP, respectively, are distinguished by the anti-id MAb2s.
血小板会因粘附素以及某些血链球菌菌株细胞表面表达的血小板聚集相关蛋白(PAAP)而发生聚集。我们试图确定血小板上相应的PAAP受体和辅助粘附素结合位点。由于血链球菌对血小板的粘附尚未得到表征,因此开发了一种抗独特型(抗id)鼠单克隆抗体(MAb2)策略。首先,选择能够区分血链球菌I 133 - 79表面粘附素和PAAP抗原的MAb1。MAb1.2(免疫球蛋白G2b [IgG2b];70 pmol)的Fab片段与5×10⁷个血链球菌细胞反应,可以完全抑制血浆中人类血小板的聚集。在类似条件下,MAb1.1(IgG1)对血链球菌细胞与血小板的粘附抑制作用最大为34%,对血小板聚集的影响相对较小。这两种MAb1共同作用时,对血链球菌与血小板的粘附抑制率为63%。在蛋白质免疫印迹中,两种MAb1均与血链球菌133 - 79的87 kDa和150 kDa表面蛋白发生反应,MAb1.2还与纯化的I型胶原发生反应。然后将产生MAb1.1和MAb1.2的杂交瘤细胞注射到BALB/c小鼠体内。采集肿大的脾脏,制备一组MAb2杂交瘤。为了鉴定针对特定MAb1的抗独特型抗体,通过酶联免疫吸附测定法筛选MAb2组,以检测其与针对87 kDa和150 kDa抗原的兔多克隆IgG抗体的反应。87 kDa和150 kDa抗原可抑制特异性兔抗体与抗独特型抗体之间的反应。当与血小板预孵育时,MAb2.1(MAb1.1的对应抗体)对血小板粘附的最大抑制率为46%,MAb2.2(抗MAb1.2)对血小板粘附的最大抑制率为35%。这两种MAb2共同作用时,对血链球菌与血小板粘附的抑制率为81%。MAb2.2还可抑制血小板聚集的诱导。MAb2.2免疫沉淀出一种170 kDa的生物素化血小板膜抗原(未还原);MAb2.